These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9371609)

  • 1. Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.
    Jurkiewicz E; Hunsmann G; Schäffner J; Nisslein T; Lüke W; Petry H
    J Virol; 1997 Dec; 71(12):9475-81. PubMed ID: 9371609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.
    Rybarczyk BJ; Montefiori D; Johnson PR; West A; Johnston RE; Swanstrom R
    J Virol; 2004 Apr; 78(7):3561-71. PubMed ID: 15016879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques.
    Meyer D; Anderson DE; Gardner MB; Torres JV
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):751-60. PubMed ID: 9643375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation.
    Torres JV; Malley A; Banapour B; Anderson DE; Axthelm MK; Gardner MB; Benjamini E
    AIDS Res Hum Retroviruses; 1993 May; 9(5):423-30. PubMed ID: 7686386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
    Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
    Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine.
    Petry H; Pekrun K; Hunsmann G; Jurkiewicz E; Lüke W
    J Virol; 2000 Dec; 74(23):11145-52. PubMed ID: 11070011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
    Chackerian B; Rudensey LM; Overbaugh J
    J Virol; 1997 Oct; 71(10):7719-27. PubMed ID: 9311856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130.
    Voss G; Dittmer U; Coulibaly C; Makoschey B; Petry H; Lüke W; Hunsmann G
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1757-63. PubMed ID: 8376957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.
    Yeh WW; Brassard LM; Miller CA; Basavapathruni A; Zhang J; Rao SS; Nabel GJ; Mascola JR; Letvin NL; Seaman MS
    J Virol; 2012 Jul; 86(13):7052-9. PubMed ID: 22532675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of B-cell epitopes in the envelope glycoproteins of simian immunodeficiency virus.
    Benichou S; Venet A; Beyer C; Tiollais P; Madaule P
    Virology; 1993 Jun; 194(2):870-4. PubMed ID: 7684879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination.
    McBride BW; Corthals G; Rud E; Kent K; Webster S; Cook N; Cranage MP
    J Gen Virol; 1993 Jun; 74 ( Pt 6)():1033-41. PubMed ID: 7685372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus.
    Almond N; Jenkins A; Jones S; Arnold C; Silvera P; Kent K; Mills KHG; Stott EJ
    J Gen Virol; 1999 Sep; 80 ( Pt 9)():2375-2382. PubMed ID: 10501490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
    Schlienger K; Montefiori DC; Mancini M; Rivière Y; Tiollais P; Michel ML
    J Virol; 1994 Oct; 68(10):6578-88. PubMed ID: 7521918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
    Burton SL; Kilgore KM; Smith SA; Reddy S; Hunter E; Robinson HL; Silvestri G; Amara RR; Derdeyn CA
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10780-5. PubMed ID: 26261312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.
    Ita S; Hill AK; Lam EC; Dufort FJ; Yang X; Newman R; Leviyang S; Fofana IB; Johnson WE
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).
    Hulskotte EG; Geretti AM; Siebelink KH; van Amerongen G; Cranage MP; Rud EW; Norley SG; de Vries P; Osterhaus AD
    J Virol; 1995 Oct; 69(10):6289-96. PubMed ID: 7666529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant.
    Sugimoto C; Nakayama EE; Shioda T; Villinger F; Ansari AA; Yamamoto N; Suzuki Y; Nagai Y; Mori K
    J Gen Virol; 2008 Feb; 89(Pt 2):554-566. PubMed ID: 18198387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
    Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
    AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.